Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199136 | 0.87 | TSHR (0.49) | NPSR1MAPK1HTTLMNAALDH1A1 | |
| SCHEMBL17420769 | 0.82 | ACSS2 (0.44) | MAPTNPSR1MAPK1HTTTSHR | |
| SCHEMBL17583195 | 0.82 | NPSR1 (0.51) | MAPTNPSR1ALDH1A1TSHRKMT2A | |
| SCHEMBL13199166 | 0.82 | TSHR (0.46) | MAPTNPSR1MAPK1HTTLMNA | |
| SCHEMBL5003336 | 0.82 | NPSR1 (0.47) | MAPTNPSR1HTTLMNATSHR | |
| SCHEMBL2396473 | 0.80 | MAPT (0.50) | MAPTNPSR1MAPK1HTTLMNA | |
| SCHEMBL31306426 | 0.80 | CA12 (0.55) | MAPTHTTALDH1A1TSHRKMT2A | |
| SCHEMBL16933517 | 0.79 | RORC (0.53) | PTGDR2ALDH1A1PTGS2RORC | |
| SCHEMBL2347249 | 0.79 | EPHX2 (0.47) | MAPTNPSR1HTTLMNAALDH1A1 | |
| SCHEMBL24614580 | 0.79 | LMNA (0.56) | MAPTNPSR1HTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2020-05-28 | — | — | US | disclosed |
| CN-111170991-A | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-106660991-B | Antiproliferative compounds and methods of use thereof | 细胞基因公司 | 2020-03-13 | — | — | CN | disclosed |
| EP-3166937-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-08-09 | — | — | US | disclosed |
| US-9968596-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2018-05-15 | — | — | US | disclosed |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-01-25 | — | — | US | disclosed |
| US-9808451-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3166937-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | Celgene Corporation (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2017-01-12 | — | — | US | disclosed |
| US-9499514-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| WO-2016007848-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | MAPT 4744/4885NPSR1 3531/4885PTGDR2 1659/4885 |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | MAPT 4744/4885NPSR1 3531/4885PTGDR2 1659/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | MAPT 4744/4885NPSR1 3531/4885PTGDR2 1659/4885 |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | MAPT 4744/4885NPSR1 3531/4885PTGDR2 1659/4885 |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | MAPT 4744/4885NPSR1 3531/4885PTGDR2 1659/4885 |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | MAPT 4744/4885NPSR1 3531/4885PTGDR2 1659/4885 |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | MAPT 4744/4885NPSR1 3531/4885PTGDR2 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.